EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders

L Corbella-Bagot, C Riquelme-McLoughlin, D Morgado-Carrasco

Actas Dermo-Sifiliográficas · 2023-10 · 114 (9) · 784-801

DOI: 10.1016/j.ad.2023.06.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2023-10. Verfasst von L Corbella-Bagot und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

JAK inhibitors target specific inflammatory cytokines involved in various inflammatory diseases. Four molecules have been approved for dermatological use: upadacitinib, baricitinib, abrocitinib and topical ruxolitinib. Off-label prescriptions for other dermatological conditions have been reported. We conducted a narrative review of the literature to assess the long-term safety profile of currently approved JAK inhibitors in dermatology, and their off-label use in skin disorders. We performed literature searches with Pubmed and Google Scholar from January 2000 to January 2023, using the keywords "Janus kinase inhibitors", "JAK inhibitors", "off-label", "dermatology", "safety", "adverse events", "ruxolitinib", "upadacitinib", "abrocitinib" and "baricitinib". Our search yielded a total of 37 dermatological disorders with studies supporting the use of these JAK inhibitors. Preliminary studies indicate that JAK inhibitors generally have a favorable safety profile and can be considered as an option in many dermatological disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsHumansOff-Label Use

Stichwörter der Autor:innen

Adverse eventsDermatologyDermatologíaEventos adversosInhibidores de JAKInhibidores de Janus kinasaJAK inhibitorsJanus kinase inhibitorsOff-labelSafetySeguridad

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain.
  • Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain; Department of Dermatology, Hospital de Figueres, Fundació Salut Empordà, Figueres, Spain. Electronic address: morgadodaniel8@gmai…

Zitieren

APA

Corbella-Bagot, L., Riquelme-McLoughlin, C., & Morgado-Carrasco, D. (2023). Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders. Actas Dermo-Sifiliográficas, 114(9), 784-801. https://doi.org/10.1016/j.ad.2023.06.012

Vancouver

Corbella-Bagot L, Riquelme-McLoughlin C, Morgado-Carrasco D. Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders. Actas Dermo-Sifiliográficas. 2023;114(9):784-801. doi:10.1016/j.ad.2023.06.012

BibTeX
@article{CorbellaBagot2023,
  author = {Corbella-Bagot, L and Riquelme-McLoughlin, C and Morgado-Carrasco, D},
  title = {Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2023},
  volume = {114},
  number = {9},
  pages = {784--801},
  doi = {10.1016/j.ad.2023.06.012}
}
Kostenlos starten →